StaniPharm Co-Authors Study on Vaping Technologies for Medical THC Delivery

StaniPharm Co-Authors Study on Vaping Technologies for Medical THC Delivery Read the publication A new study published in the Journal of Drug Delivery Science and Technology evaluates two vaping technologies for delivering medical THC by inhalation, a CE-marked medical device…

StaniPharm has manufactured clinical batches of Muco-Excipient for Lovaltech’s intranasal vaccine, as the MUCOBOOST clinical trial gets underway

On 14 March 2025, Lovaltech announced the launch of MUCOBOOST, the First-in-Human clinical trial for its intranasal vaccine candidate

StaniPharm and LiteVax bring a novel vaccine adjuvant from bench to First-in-Human trial in the INDIGO consortium

Developed by Dutch biotech LiteVax and manufactured by StaniPharm, the adjuvant is at the heart of the EU-India INDIGO consortium's effort to build more accessible, dose-sparing influenza vaccines.

Medical Cannabis: a crucial step towards a French ecosystem

Pharmaceutical companies qualified to manufacture either active substances or medicines will now be able to produce cannabis-based medicines in France.

A look back at some of 2021’s key highlights at StaniPharm

Manufacturing of clinical GMP batches of a new vaccine adjuvant, development and manufacturing of innovative cannabis-based medicines, medical cannabis in France ...

Vaxinano partners with StaniPharm for development and production of its vaccine delivery system

"Scaling up this kind of vaccine delivery system is a crucial step and requires a strong partner" says Dr. Didier Betbeder, CEO of Vaxinano.

Developing a French “patient to seed” ecosystem to improve the therapeutic benefit of medical Cannabis

"Simply replacing the imported products currently specified for the pilot program with French-produced equivalents would be a missed opportunity and a disservice to patients"

Cybernano and StaniPharm join forces to develop tomorrow’s health products

The complementary nature of their expertise and technologies will provide complete support for start-ups and SMEs from development through clinical trials.

Drug nanoparticles – a common approach to tackle the poor aqueous solubility of APIs

Nanosizing drug particles brings key benefits for oral formulations of poorly soluble drugs such as Biopharmaceutics Classification System (BCS) Class II drugs.

8 supercritical companies inspired by Michel Perrut, founder of SEPAREX

SEPAREX, the gold standard in supercritical fluids, was founded in 1985 by Michel Perrut. SEPAREX was also a pioneering business incubator, far ahead of its time, contributing to the birth of 8 companies.